Difference 47000000 exceeds tolerance 8603000.000. Presentation or filing-vintage differences need review.
DENTSPLY SIRONA Inc. (XRAY) reported revenue of $3.68B and net income of -$598.00M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from DENTSPLY SIRONA Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Dental Equipment & Supplies.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.68B | $3.79B | $3.96B | $3.92B | $4.23B | $3.34B | $4.02B | $3.99B | $3.99B | $3.75B |
| Cost of revenue | $1.84B | $1.84B | $1.88B | $1.80B | $1.88B | $1.68B | $1.86B | $1.92B | $1.80B | $1.74B |
| Gross profit | $1.84B | $1.96B | $2.09B | $2.13B | $2.35B | $1.66B | $2.16B | $2.07B | $2.19B | $2.00B |
| Operating income | -$422.00M | -$879.00M | -$85.00M | -$937.00M | $608.00M | -$3.00M | $353.00M | -$958.00M | -$1.56B | $454.70M |
| Net income | -$598.00M | -$910.00M | -$132.00M | -$950.00M | $411.00M | -$73.00M | $256.00M | -$1.01B | -$1.55B | $429.90M |
| Research & development | $150.00M | $165.00M | $184.00M | $174.00M | $171.00M | $123.00M | $143.00M | $161.00M | $151.70M | $128.50M |
| Weighted-average diluted shares | shares 199.40M | shares 203.20M | shares 212.00M | shares 215.50M | shares 220.20M | shares 219.20M | shares 224.40M | shares 224.30M | shares 229.40M | shares 221.60M |
| Pretax income | -$486.00M | -$936.00M | -$175.00M | -$1.06B | $545.00M | -$50.00M | $338.00M | -$958.00M | -$1.60B | $440.90M |
| Income tax expense | $112.00M | -$26.00M | -$43.00M | -$105.00M | $134.00M | $23.00M | $82.00M | $53.00M | -$53.20M | $9.50M |
| Diluted EPS | $-3.00 | $-4.48 | $-0.62 | $-4.41 | $1.87 | $-0.33 | $1.14 | $-4.51 | $-6.76 | $1.94 |
| Selling, general & administrative | $1.44B | $1.60B | $1.61B | $1.59B | $1.55B | $1.30B | $1.59B | $1.72B | $1.67B | $1.52B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $326.00M | $272.00M | $334.00M | $365.00M | $339.00M | $438.00M | $405.00M | $309.60M | $320.60M | $383.90M |
| Total assets | $5.43B | $5.75B | $7.37B | $7.64B | $9.24B | $9.35B | $8.60B | $8.69B | $10.37B | $11.56B |
| Current assets | $2.02B | $1.75B | $1.97B | $1.89B | $1.85B | $1.80B | $2.00B | $1.89B | $2.00B | $1.74B |
| Total liabilities | $4.09B | $3.81B | $4.08B | $3.83B | $4.24B | $4.42B | $3.51B | $3.55B | $3.75B | $3.43B |
| Current liabilities | $1.34B | $1.59B | $1.42B | $1.17B | $1.26B | $1.37B | $995.00M | $1.01B | $954.50M | $767.60M |
| Total equity incl. NCI | $1.34B | $1.94B | $3.29B | $3.81B | $5.00B | $4.94B | $5.05B | $5.08B | $6.63B | $8.13B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $642.00M | $564.00M | $624.00M | $627.00M | $515.00M | $476.00M | $562.00M | $598.90M | $623.10M | $517.10M |
| Accounts receivable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Goodwill | $1.15B | $1.60B | $2.44B | $2.69B | $3.98B | $3.99B | $3.40B | $3.43B | $4.54B | $5.95B |
| Long-term debt | $2.02B | $1.59B | $1.80B | $1.83B | $1.91B | $1.98B | $1.43B | $1.56B | $1.61B | $1.51B |
| Accounts payable | $300.00M | $241.00M | $305.00M | $279.00M | $262.00M | $302.00M | $308.00M | $283.90M | $284.40M | $223.00M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $235.00M | $461.00M | $377.00M | $517.00M | $657.00M | $649.00M | $639.00M | $500.00M | $601.90M | $563.40M |
| Capital expenditures | Unavailable | Unavailable | Unavailable | $149.00M | $142.00M | $87.00M | $123.00M | $183.00M | $144.30M | Unavailable |
| Investing cash flow | -$132.00M | -$197.00M | -$89.00M | -$138.00M | -$358.00M | -$1.11B | -$69.00M | -$253.00M | -$286.40M | $60.00M |
| Financing cash flow | -$80.00M | -$302.00M | -$307.00M | -$329.00M | -$379.00M | $476.00M | -$472.00M | -$250.00M | -$400.80M | -$526.20M |
| Net change in cash | $54.00M | -$62.00M | -$31.00M | $26.00M | -$99.00M | $33.00M | $95.00M | -$11.00M | -$63.30M | $99.30M |
| Stock-based compensation | $33.00M | $39.00M | $46.00M | $59.00M | $48.00M | $47.00M | $66.00M | $21.00M | $48.00M | $41.30M |
| Common dividends paid | $128.00M | $126.00M | $116.00M | $104.00M | $92.00M | $88.00M | $81.00M | $79.00M | $78.30M | $64.60M |
| Common share repurchases | $0 | $250.00M | $300.00M | $150.00M | $200.00M | $140.00M | $260.00M | $250.00M | $401.40M | $813.90M |
| Depreciation & amortization | $352.00M | $349.00M | $343.00M | $328.00M | $347.00M | $334.00M | $323.00M | $331.00M | $316.40M | $271.70M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $562.00M | $516.00M | $317.00M | $457.60M | Unavailable |
| Gross margin | 50.0% | 51.6% | 52.6% | 54.2% | 55.5% | 49.6% | 53.8% | 51.9% | 54.8% | 53.4% |
| Operating margin | -11.5% | -23.2% | -2.1% | -23.9% | 14.4% | -0.1% | 8.8% | -24.0% | -39.1% | 12.1% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 16.8% | 12.8% | 8.0% | 11.5% | Unavailable |
| SBC / revenue | 0.9% | 1.0% | 1.2% | 1.5% | 1.1% | 1.4% | 1.6% | 0.5% | 1.2% | 1.1% |
| Current ratio | 1.51x | 1.10x | 1.38x | 1.62x | 1.47x | 1.31x | 2.01x | 1.86x | 2.10x | 2.27x |
| Revenue YoY growth | -3.0% | -4.3% | 1.1% | -7.3% | 26.7% | -17.0% | 0.9% | -0.2% | 6.6% | Unavailable |
| Net margin | -16.2% | -24.0% | -3.3% | -24.2% | 9.7% | -2.2% | 6.4% | -25.4% | -38.8% | 11.5% |
| R&D / revenue | 4.1% | 4.4% | 4.6% | 4.4% | 4.0% | 3.7% | 3.6% | 4.0% | 3.8% | 3.4% |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 2.6% | 3.1% | 4.6% | 3.6% | Unavailable |
| Long-term debt / equity | 1.50x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | 24.6% | Unavailable | 24.3% | Unavailable | Unavailable | 2.2% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open XRAY in the interactive workspace to inspect any figure back to its filing.
Source filings
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
Difference 50000000 exceeds tolerance 8687000.000. Presentation or filing-vintage differences need review.